Zydus receives USFDA approval for Phytonadione and Colchicine Tablets

Zydus Cadila has received the final approval from the USFDA to market Phytonadione Tablets. The group also received the final approval for Colchicine Tablets USP (US RLD - Colcrys), 0.6 mg.

Phytonadione is Vitamin K1 and is used to treat and prevent low levels of blood clotting factors that the body naturally produces. These substances help in thickening of the blood and stop the bleeding normally.

Colchicine is used to prevent or treat attacks of gout. This condition is caused by high uric acid levels in the blood. This medication is also used to prevent attacks of pain in the abdomen, chest or joints caused by a genetic auto-inflammatory disease called as familial Mediterranean fever.

Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

On Thursday, the stock of Cadila opened at Rs. 314.05 per share against Wednesday’s close of Rs. 313.60. The stock closed at Rs. 313.25 per share, up by 0.11 per cent.